Sonnet BioTherapeutics shareholders approve proposed business merger with Hyperliquid Strategies Inc.

According to a press release from Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), Sonnet announced that its shareholders approved, at a special meeting, matters including a proposed business merger with Hyperliquid Strategies Inc. (HSI) and Rorschach I LLC.

The final vote will be submitted to the U.S. Securities and Exchange Commission (SEC) on Form 8-K. Sonnet is a biotechnology company focused on oncology with a proprietary biologics innovation platform, FHAB (Fully Human Albumin Binding). This technology utilizes human serum albumin (HSA) to deliver drugs to target tissues, aiming to improve the safety and efficacy of immunomodulatory biologics.

Under the proposed business merger transaction, HSI's Form S-4 registration statement, which includes a proxy statement for Sonnet shareholders and will also constitute HSI's prospectus, became effective on October 27. Upon completion of the proposed business merger, HSI's securities are expected to be listed on Nasdaq.